Sector Expert: Russell Stanley

Mackie Research Capital

Image: Russell Stanley

Russell Stanley, vice president at Mackie Research Capital, is a special situations analyst whose primary focuses are industrial products and energy services. Prior to joining Mackie Research Capital in December 2014, Stanley was a special situations analyst at Jennings Capital Inc. Stanley has 18 years of experience in the brokerage industry, including 11 years in equity research. He received his master's degree in business administration (Finance and Strategy) from the Schulich School of Business, York University, and is a CFA charterholder.

Subscribe to
Streetwise Reports

Companies Commented On

  • Convalo Health International Corp.
  • Nobilis Health Corp.
  • Patient Home Monitoring Corp.


Recent Interviews

Growth by Acquisition Is Solid: Russell Stanley of Mackie Research Capital (12/23/15)
fist-full-of-dollars630

The traditional biotech investor wants to hit the lottery with a blockbuster molecule, but there are less risky avenues to profit, where capital is deployed to leverage the healthcare market via reimbursement from Medicare, the Affordable Care Act and private-pay insurance. In this interview with The Life Sciences Report, Russell Stanley of Mackie Research Capital tells investors that growth is where you find it, including in acquisitions. Stanley offers three names that, based on his current target prices, offer investors potential returns of more than 100%.

Keep Truckin': Russell Stanley on How to Snap Up Growing Energy Services Companies (9/25/14)
frozenoilrig580

energy servicesThe oil and gas fields in western Canada are sucking up rental equipment, trucking services and well site accommodation services like the proverbial black hole. Russell Stanley of Jennings Capital, an expert on mergers and acquisitions, knows how to find the margin in the increasingly profitable energy service industry, and explains the rules of this investment game to The Energy Report.

Recent Quotes

"We view HLTH's results as demonstrating solid sequential improvement in terms of margins, receivables collection and financial reporting timeliness."

— Russell Stanley, Mackie Research Capital (8/4/16)
more >

"HLTH's [Q2/16] results demonstrated sequential revenue and EBITDA improvement from Q1/16 levels, reflecting seasonality in the business."

— Russell Stanley, Mackie Research Capital (8/3/16)
more >

"We like HLTH's acquisition of Arizona Vein & Vascular Center, as it expands the company's presence in Arizona and augments the service breadth."

— Russell Stanley, Mackie Research Capital (8/2/16)
more >

"We view Mr. Ken Efird's appointment positively, as it represents a promotion-from-within HLTH for a very capable executive."

— Russell Stanley, Mackie Research Capital (7/11/16)
more >

"HLTH is an undervalued play on growing demand for high acuity surgery in the U.S."

— Russell Stanley, Mackie Research Capital (5/25/16)
more >

"HLTH is an undervalued play on growing demand for high acuity surgery; it's a Buy."

— Russell Stanley, Mackie Research Capital (5/3/16)
more >

"HLTH is an undervalued, overlooked play on growing demand for high acuity surgical procedures."

— Russell Stanley, Mackie Research Capital (3/28/16)
more >

"HLTH's change to now consider 'distressed asset' deals is positive."

— Russell Stanley, Mackie Research Capital (3/17/16)
more >

more comments

"HLTH reported Q4 results that beat our estimates for revenue."

— Russell Stanley, Mackie Research Capital (3/16/16)
more >

"HLTH's timely Q4/15 reporting should further derisk the stock."

— Russell Stanley, Mackie Research Capital (3/11/16)
more >

"Recently, HLTH's CEO acquired 31.7K shares, and other insiders, 21K."

— Russell Stanley, Mackie Research Capital (2/2/16)
more >

"HLTH's reiteration of FY16 guidance is a strong positive."

— Russell Stanley, Mackie Research Capital (1/20/16)
more >

"HLTH currently trades at a discount that is unreasonably high."

— Russell Stanley, Mackie Research Capital (1/15/16)
more >

"HLTH is likely to announce an acquisition in Q1/16."

— Russell Stanley, Mackie Research Capital (1/14/16)
more >

"HLTH's release of its financials should be a major lift to the stock."

— Russell Stanley, Mackie Research Capital (1/13/16)
more >

"Potential catalysts for HLTH include the Q3/15 results and M&A."

— Russell Stanley, Mackie Research Capital (1/8/16)
more >

"HLTH management's breakdown of restatement items is a silver lining."

— Russell Stanley, Mackie Research Capital (1/6/16)
more >

"HLTH gives investors access to a market that's otherwise predominately privately held."

The Life Sciences Report Interview with Russell Stanley (12/23/15)
more >

"HLTH's relationship with its lender is in good standing."

— Russell Stanley, Mackie Research Capital (12/9/15)
more >

"Near-term release of HLTH's Q3/15 results should derisk the stock."

— Russell Stanley, Mackie Research Capital (12/3/15)
more >

"HLTH's Q3/15 preliminary results point to a strong quarter."

— Russell Stanley, Mackie Research Capital (11/25/15)
more >

"We view HLTH's Q3/15 preliminary results positively."

— Russell Stanley, Mackie Research Capital (11/12/15)
more >

"Guidance from HLTH's management should be the investor focus."

— Russell Stanley, Mackie Research Capital (11/11/15)
more >

"HLTH completed its acquisition of the Freedom Pain Hospital."

— Russell Stanley, Mackie Research Capital (11/6/15)
more >

"Litigation against the blog should give assurance to NHC investors."

— Russell Stanley, Mackie Research Capital (11/4/15)
more >

"The independent counsel's report substantially de-risks NHC's stock."

— Russell Stanley, Mackie Research Capital (11/4/15)
more >

"Nobilis Health Corp. is our top pick in the special situations category."

— Russell Stanley, Mackie Research Capital (11/3/15)
more >

"A solid Q3/15 report should improve investor confidence in HLTH."

— Russell Stanley, Mackie Research Capital (10/26/15)
more >

"HLTH remains undervalued relative to comparable companies."

— Russell Stanley, Mackie Research Capital (10/20/15)
more >

"HLTH supports an independent review of the recent allegations it."

— Russell Stanley, Mackie Research Capital (10/19/15)
more >

"In the next six months, HLTH should produce more positive news flow."

— Russell Stanley, Mackie Research Capital (10/15/15)
more >

"HLTH's share price response on Friday creates a buying opportunity."

— Russell Stanley, Mackie Research Capital (10/12/15)
more >

"We view HLTH as an undervalued play."

— Russell Stanley, Mackie Research Capital (10/7/15)
more >

"HLTH's deal to acquire 60% of Freedom Pain Hospital is positive."

— Russell Stanley, Mackie Research Capital (9/23/15)
more >

"HLTH is very attractively priced at current levels."

— Russell Stanley, Mackie Research Capital (9/21/15)
more >

"HLTH is significantly undervalued relative to its peers."

— Russell Stanley, Mackie Research Capital (9/16/15)
more >

"We reiterate our Buy recommendation on HLTH."

— Russell Stanley, Mackie Research Capital (8/31/15)
more >

"HLTH's Q2/15 results beat our estimates and consensus."

— Russell Stanley, Mackie Research Capital (8/17/15)
more >

"HLTH's Q2/15 revenue and EBITDA beat consensus and our estimates."

— Russell Stanley, Mackie Research Capital (8/14/15)
more >

"We continue to view HLTH as an attractively priced play on the U.S. health care market."

— Russell Stanley, Mackie Research Capital (7/30/15)
more >

"NHC's new CFO, Kenny Klein, adds post-transaction integration experience."

— Russell Stanley, Mackie Research Capital (7/9/15)
more >

"HLTH is an attractively priced play on the U.S. healthcare market."

— Russell Stanley, Mackie Research Capital (6/18/15)
more >

"We continue to believe HTLH is undervalued."

— Russell Stanley, Mackie Research Capital (6/8/15)
more >

"HLTH's expertise in direct-to-patient marketing is unique."

— Russell Stanley, Mackie Research Capital (5/21/15)
more >

"NHC's Q1/15 revenue beat can be attributed to strong case volumes."

— Russell Stanley, Mackie Research Capital (5/15/15)
more >

"HLTH has added annualized revenue capacity of up to $150M."

— Russell Stanley, Mackie Research Capital (5/14/15)
more >

"Listing on the NYSE.MKT should broaden NHC's potential investor base."

— Russell Stanley, Mackie Research Capital (4/15/15)
more >

"NHC's warrants should add $2.1M in cash that should support growth."

— Russell Stanley, Mackie Research Capital (4/14/15)
more >

"We continue to view NHC as an attractively priced U.S. healthcare play."

— Russell Stanley, Mackie Research Capital (4/9/15)
more >

"The $25M debt facility is positive; it reduces NHC's borrowing costs."

— Russell Stanley, Mackie Research Capital (4/2/15)
more >

"NHC is an attractively priced play in the U.S. healthcare market."

— Russell Stanley, Mackie Research Capital (3/26/15)
more >

"There is substantial upside to revenue and EBITDA forecasts for NHC."

— Russell Stanley, Mackie Research Capital (3/24/15)
more >

"NHC is an attractively priced play on the U.S. health care market."

— Russell Stanley, Mackie Research Capital (3/9/15)
more >

"We are initiating coverage on NHC with a Buy recommendation."

— Russell Stanley, Mackie Research Capital (2/26/15)
more >

"We are initiating coverage of NHC with a Buy recommendation."

— Russell Stanley, Mackie Research Capital (2/26/15)
more >

"E reported Q3/14 revenue of $18.8M and cash and equivalents of $8.6M."

— Russell Stanley, Jennings Capital (11/14/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.